Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc)(Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc))

概要

基本信息

药物类型

灭活疫苗、联合疫苗、预防性疫苗

+ [1]

别名

Boostrix、dTpa vaccine、Refortrix

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病其他疾病

在研适应症

白喉破伤风百日咳

非在研适应症-

原研机构

GSK Plc

在研机构

GlaxoSmithKline GmbH & Co. KGGlaxoSmithKline LLC

GSK Plc

非在研机构-

权益机构

GSK Plc

SK bioscience Co., Ltd.

最高研发阶段批准上市

首次获批日期

奥地利 (2000-10-03),

白喉破伤风百日咳

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

关联

49

项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的临床试验

NCT07097012

/ Recruiting临床4期IIT

Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy - A Pilot Feasibility Trial

The goal of this clinical trial is to learn if the RSV vaccine (protects against respiratory syncytial virus) and Tdap vaccine (protects against pertussis) are most effective in pregnant individuals when taken together at the same visit, or separately at different visits. This clinical trial will also learn about the safety and immune responses of these vaccines in pregnancy.
The Main question:
-Is it possible to run a successful trial that tests how safe and effective it is to give Tdap and RSV vaccines in pregnancy either at the same time or one after the other, at different visits?
The Secondary question:
-To determine how safe and how well the Tdap and RSV vaccines work when given in pregnancy either at the same time or one after the other, at different visits.
The Exploratory (optional participation) questions:
* To measure the levels of antibodies against whooping cough (pertussis) and RSV in mothers at 7 and 19 months after giving birth, depending on whether they got the vaccines at the same time or one after the other during pregnancy.
* To measure whooping cough antibody levels in the babies at 2, 7, and 19 months of age, whose mothers who received the vaccines in pregnancy.
* To measure the levels of RSV antibodies in the mothers' breast milk at 1 week, 2 weeks, 4 weeks, and 2 months after giving birth.
Participants will be randomly assigned to Group 1 (vaccines given at the same time, same visit) or Group 2 (vaccines given one after the other, at different visits).
There are 4 visits as part of the main study, and 6 additional visits as part of the optional study (exploratory questions).
Visit 1-2: Blood collection and vaccines administered Visit 3-4: Blood work (cord blood sample collection from infant, after delivery, if possible) Visit 5-8: Breast milk collection Visit 8-10: Blood collection (infant blood collection only at Visit 8).
Participants will be asked to keep a diary of symptoms throughout the study.

开始日期2025-10-16

申办/合作机构

Canadian Immunization Research Network

[+6]

NCT06494475

/ Not yet recruiting临床2/3期

A Randomised, Observer-Blind Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of a Group B Streptococcus Vaccine (GBS-NN/NN2) When 1 Dose is Administered Concomitantly With the Tdap Vaccine in Healthy-non Pregnant Women 18 to 49 Years of Age Compared to When Each Vaccine is Administered Alone

The main objectives of the study are to demonstrate the non-inferiority of the immune response induced by co administered GBS-NN/NN2 and tetanus, diphtheria, and acellular pertussis (Tdap) compared to the separate administration of GBS-NN/NN2 and Tdap, to evaluate the reactogenicity of GBS NN/NN2 when administered alone or in combination with Tdap, and to evaluate the safety of GBS-NN/NN2 when administered alone or in combination with Tdap in terms of serious adverse events (SAEs) and unsolicited adverse events (AEs).

开始日期2024-12-17

申办/合作机构

MinervaX ApS

NCT06015308

/ Completed临床2期

A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis

This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD).
The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis [Tdap]) and Pneumovax 23 (PPSV) vaccines in adult participants with moderate-to-severe AD treated with amlitelimab versus placebo. The study will evaluate the percentage of participants achieving a positive anti-tetanus response at Week 16 (primary endpoint) and a positive anti-pneumococcal response at Week 16 (key secondary endpoint).
Study details include:
The study duration will be up to 36 weeks (for participants not entering the LTS17367 [RIVER-AD]).
The screening period will be 9 days to 4 weeks. The treatment duration will be up to 16 weeks. The post-treatment safety follow-up period will be16 weeks. The number of visits will be up to 7 (or 6 for those entering LTS17367 [RIVER-AD]).

开始日期2023-10-06

申办/合作机构

Sanofi

100 项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的临床结果

登录后查看更多信息

100 项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的转化医学

登录后查看更多信息

100 项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的专利（医药）

登录后查看更多信息

280

项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的文献（医药）

2026-03-01·VACCINE

Immunological responses to tetanus, diphtheria, pertussis (Tdap) vaccine in Brazilian hematopoietic stem cell transplant recipients

Article

作者: Oliveira, Maria Carolina ; Costa, Thalita Cristina Mello ; Achcar, Jorge Alberto ; Bellissimo-Rodrigues, Fernando ; Darrigo-Junior, Luiz Guilherme ; Paternina-De La Ossa, Rolando ; Zanin-Silva, Djúlio César

INTRODUCTION:

Among hematopoietic stem cell transplant (HSCT) recipients, morbidity and mortality are largely related to infectious diseases, many of which are vaccine-preventable. The present study aimed to assess the immune response of HSCT patients to the tetanus, diphtheria, and acellular pertussis inactivated vaccine (Tdap).

PATIENTS AND METHODS:

This quasi-experimental study, with individually matched data collection in HSCT patients from January 2018 to December 2020, evaluated sixteen patients for their immune response to each of the Tdap components. The immunization schedule included three doses of Tdap, with a minimum interval of 30 days between each dose, starting at 6 months post-transplantation. Immune competence was measured before vaccination by quantifying CD4+, CD8+, and CD19+ frequencies, as well as serum immunoglobulin levels.

RESULTS:

After the complete immunization schedule, for diphtheria, we observed a Geometric Mean Concentration (GMC) rise from 0.2509 IU/mL at baseline to 0.7544 IU/mL post-vaccination, p = 0.001. For tetanus, GMC increased from 0.353 to 1.153 IU/mL, p = 0.001. For pertussis, GMC was 31.9 IU/mL before and 99.3 IU/mL after vaccination. Due to the non-normal distribution of pertussis data and a marginal frequentist result (p = 0.077), we used Bayesian analysis assuming an exponential distribution. This model identified a significant increase in antibody levels, with a posterior mean difference (θ) of 58.55 IU/mL and a 95% Credibility Interval (23.9-109.0) that excluded zero, confirming an adequate vaccine response. For the entire Tdap vaccination period, CD4+ cell frequencies remained low, while CD8+, CD19+, and immunoglobulin titers remained within normal range. Immune responses to each of the Tdap vaccine components were not affected (p > 0.05) by any of the clinical, demographic, or immunological variables assessed.

CONCLUSIONS:

The overall Tdap vaccine post-transplant response was considered adequate for diphtheria, tetanus, and pertussis. These findings highlight the immune response to Tdap in transplanted patients and may inform future vaccination guidelines.

2026-02-01·VACCINE

Impact of pregnancy on longitudinal pertussis antibody responses to Tdap vaccine in Guatemala

Article

作者: Sundaram, Maria ; Maldonado, Herberth ; Bednarczyk, Robert A ; McCracken, John P ; Phadke, Varun K ; Omer, Saad B

Maternal immunization with tetanus, diphtheria, and acellular pertussis (Tdap) vaccine is recommended in many countries, but coverage in many low-income countries remains suboptimal. Targeted vaccination of women of child-bearing age could be a supplemental strategy to address this gap, but there are limited longitudinal immunogenicity data in this population outside of high-income countries. We compared antibody responses to Tdap between 30 non-pregnant women and 156 pregnant women enrolled in a clinical trial of maternal Tdap vaccination in Guatemala. Pre-vaccination antibody concentrations among both groups were similar for all vaccine antigens. At 2 months post-vaccination, antibody concentrations against vaccine antigens increased in both groups and were higher among non-pregnant women. By 9 months, antibody concentrations had decayed and were no longer different by study group. These findings reinforce existing recommendations for Tdap vaccination with every pregnancy. Vaccination of non-pregnant women may be considered in settings where maternal Tdap coverage is low.

2026-01-01·LANCET INFECTIOUS DISEASES

Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: a phase 1 randomised controlled trial

Article

作者: Berlanda Scorza, Francesco ; Nigro, Simona ; Rondini, Simona ; De Coster, Ilse ; Conti, Valentino ; Massai, Luisa ; Rossi, Omar ; La Gaetana, Rita ; Serry-Bangura, Alimamy ; Luna Cilio, Giulia ; AbdelGhany, Mohammad ; Fineschi, Chiara ; Withanage, Kanchanamala ; Carducci, Martina ; Van Damme, Pierre ; Tessitore, Pietro ; Nakakana, Usman N ; Micoli, Francesca ; Sarakinou, Eleanna ; Kumar Arora, Ashwani ; Marchetti, Elisa

BACKGROUND:

Enteric fever caused by Salmonella enterica serovars Typhi and Paratyphi A remains a major concern. No vaccines are licensed against Salmonella Paratyphi A. We aimed to assess the safety and immunogenicity of an investigational conjugate vaccine against Salmonella Typhi and Paratyphi A (Vi-CRM₁₉₇+O:2-CRM₁₉₇).

METHODS:

In this observer-masked, randomised, controlled, dose-escalation, single-centre, phase 1 trial done during Nov 28, 2022, to April 2, 2024, at the Centre for Evaluation of Vaccination in Belgium, healthy adults (aged 18-50 years) were randomly assigned (2:1 or 2:2:1 across different steps using sealed envelopes following a randomisation schedule generated by an independent statistician) to receive two intramuscular doses (on day 1 and day 169) of one of four Vi-CRM₁₉₇+O:2-CRM₁₉₇ formulations (low dose or full dose, with or without aluminium hydroxide) or a control vaccine (Vi capsular polysaccharide vaccine and diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine for first and second dose). The primary outcome was vaccine safety (solicited events during 7 days and unsolicited adverse events during 28 days after vaccination, serious adverse events [SAEs], and adverse events or SAEs leading to study withdrawal or withholding of further study intervention administration from day 1 to day 197, and deviations from normal or baseline laboratory test values 7 days after vaccination). Secondary outcomes included long-term vaccine safety (SAEs and adverse events or SAEs leading to study withdrawal from day 197 to day 337), and immunogenicity, including anti-Vi and anti-O:2 IgG antibody geometric mean concentrations and geometric mean ratios (GMRs) by ELISA, and seroresponses (percentages of participants with anti-Vi IgG concentrations ≥4·3 μg/mL and ≥2·0 μg/mL; ≥4-fold anti-O:2 IgG concentration increase from baseline) at day 1 (as applicable), day 29, day 169, day 176, and day 197. Safety analyses were done on the solicited safety set, unsolicited safety set, and the exposed set. The primary immunogenicity analysis was done on the per-protocol set defined by timepoint. The trial is registered with ClinicalTrials.gov (NCT05613205) and gsk-studyregister.com (205480), and is completed.

FINDINGS:

96 participants were randomly assigned, 12 to each low-dose group, 24 to each full-dose group, and 24 to the control group. The incidence of solicited administration-site events (mostly pain) ranged from six (50% [95% CI 21·1-78·9]) of 12 participants in the low-dose without aluminium hydroxide group to 23 (96% [78·9-99·9]) of 24 in the full-dose with aluminium hydroxide group, versus 22 (92% [73·0-99·0]) of 24 in the control group. Solicited systemic events (mostly fatigue, headache, and myalgia) ranged from eight (67% [34·9-90·1]) of 12 in the low-dose groups to 20 (83% [62·6-95·3]) of 24 in the full-dose with aluminium hydroxide group, versus 21 (88% [67·6-97·3]) of 24 in the control group. The incidence of unsolicited adverse events (mostly nasopharyngitis) ranged from seven (58% [27·7-84·8]) of 12 in the low-dose without aluminium hydroxide group to ten (83% [51·6-97·9]) of 12 in the low-dose with aluminium hydroxide group, versus 14 (58% [36·6-77·9]) of 24 in the control group. Most safety laboratory results were within reference ranges. No SAEs occurred. After dose 1 (ie, at day 29), full-dose without aluminium hydroxide and full-dose with aluminium hydroxide induced the highest anti-Vi IgG responses (GMR 53·01 [95% CI 31·94-87·99] and 31·55 [18·74-53·11], respectively) versus control (4·50 [2·93-6·90]). Full-dose without aluminium hydroxide and low-dose without aluminium hydroxide induced the highest anti-O:2 IgG responses after dose 1 (GMR 162·61 [91·17-290·04] and 114·19 [44·83-290·86], respectively), versus control (1·27 [1·02-1·60]). 89-100% and 82-100% of participants (lowest percentages for low-dose with aluminium hydroxide) had anti-Vi IgG ≥4·3 μg/mL at day 29 (in initially seronegative participants) and ≥4-fold anti-O:2 IgG increase from baseline, respectively, versus 13 (54% [95% CI 32·8-74·4]) and one (4% [0·1-21·1]) of 24 participants in the control group, respectively. The second dose did not boost the responses.

INTERPRETATION:

Vi-CRM₁₉₇+O:2-CRM₁₉₇ formulations did not raise safety concerns and showed immunogenicity with a single dose, supporting further clinical assessment of the full-dose without aluminium hydroxide in target populations (infants and older age groups) in endemic regions.

FUNDING:

Wellcome Trust.

27

项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的新闻（医药）

2026-03-11

·EINPresswire

Whooping Cough Continues Wyoming Spread

March 11, 2026 Wyoming Department of Health (WDH) officials are concerned about the ongoing, active spread of pertussis (whooping cough) across the state. Kaylyn Friesen, vaccine-preventable disease epidemiologist with WDH, said there have been 26 confirmed pertussis cases in Wyoming so far this year. “While roughly two-thirds of the reported cases have been among Fremont County residents, pertussis has also been identified in other counties,” Friesen said. Friesen noted that 148 cases were reported in Wyoming in 2025, the highest since 1951. “We are continuing to see outbreaks and high monthly case counts,” Friesen said. Actual case numbers are likely higher because many illnesses are not recognized as pertussis, and others may not be reported. Pertussis typically begins with cold-like symptoms and perhaps a mild cough. Pertussis is often not suspected or diagnosed until a persistent cough with spasms develops after 1 to 2 weeks. Infants and children can cough violently and rapidly with a loud “whooping” sound. Dr. Alexia Harrist, state health officer with WDH, said, “One-third of infants less than 1 year of age who become ill with pertussis need to be hospitalized, and we know, in some cases, it can be deadly for these babies. Pertussis in the youngest babies can cause them to have pauses in breathing. Infants are simply more vulnerable and don’t yet have all the protection pertussis vaccines offer.” Harrist said the Tdap adolescent/adult pertussis booster vaccine is especially important for those spending time with new infants, such as parents, grandparents, and other people who take care of them. “Also, if you are pregnant or planning on becoming pregnant, you should talk to your doctor about a Tdap vaccine because that can also help protect newborns,” she said. Harrist recommends that all residents stay up to date with pertussis vaccines, as those who still become ill with pertussis after vaccination are less likely to have a severe experience. “In addition, people should consider seeing a medical professional for antibiotics if they have symptoms consistent with pertussis,” she said. More information about pertussis can be found online at https://health.wyo.gov/publichealth/infectious-disease-epidemiology-unit/disease/pertussis/ . Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

疫苗

2026-01-09

·drugs

Maternal Flu, Tdap Shots May Lower Rates of Infant Hospitalization, ED Visits

FRIDAY, Jan. 9, 2026 -- Maternal influenza and tetanus-diphtheria-acellular pertussis (Tdap) vaccinations are associated with a lower risk for influenza- and pertussis-related hospitalization or emergency department (ED) visits in infants younger than 6 months, according to a study published online Jan. 8 in JAMA Network Open . Gabriella Morabito, from the National Centre for Healthcare Research and Pharmacoepidemiology at the University of Milano-Bicocca Milan in Italy, and colleagues conducted a population-based cohort study using health care utilization databases from the Lombardy region of Italy to examine the association of maternal influenza and Tdap vaccinations with influenza- and pertussis-related hospitalizations and ED visits among infants aged younger than 6 months. A total of 53,448 pregnant individuals who received the Tdap vaccine and 5,347 who received the influenza vaccine were included in the study. Maternal vaccination coverage was 6.4 and 41.0 percent for influenza and Tdap, respectively. The researchers found that the risk for hospitalization or ED visits for influenza and pertussis was lower among infants born to mothers who received the influenza and Tdap vaccines (vaccine effectiveness, 69.7 and 88.6 percent, respectively). "These results support the current recommendations for administering these vaccines during pregnancy and highlight the urgent need to implement strategies aimed to increase their acceptance," the authors write. One author disclosed ties to the pharmaceutical industry. Abstract/Full Text

疫苗临床结果

2025-11-20

·drugs

Whooping Cough Surges Nationwide as Vaccinations Fall

THURSDAY, Nov. 20, 2025 — Whooping cough is making a major comeback in the United States, with sharp increases now seen in Texas, Florida, California, Oregon and many other places. Health officials say the latest rise in pertussis cases is being driven by falling vaccination rates, waning immunity and slower public health tracking systems. What's more, officials say, is that babies remain the most vulnerable. "Pertussis cases increase in a cyclical fashion driven by waning immunity," Dr. Demetre Daskalakis , former head of the U.S. Centers for Disease Control and Prevention's (CDC) immunization program, told CBS News . "But the size of the outbreak and the potential for severe outcomes in children who cannot be vaccinated can be mitigated by high coverage and good communication to folks at risk," he added. Before a vaccine was introduced in the early 1900s, whooping cough was one of the leading causes of childhood death in the United States. Today, routine vaccination starts at 2 months old and continues through adulthood with booster shots. But the pandemic brought a drop in vaccine uptake and nonmedical exemptions in some states have widened immunity gaps. Texas illustrates how quickly case numbers have grown. The state reported 1,928 cases in 2024. By October 2025, that number had already climbed past 3,500. National trends are just as shocking. In the first three months of 2025, the United States counted 6,600 pertussis cases, four times last year’s pace and 25 times the pace in 2023. Outbreaks in places like Louisiana, South Dakota and Idaho show the problem is not limited to just one region of the country. Texas recently made it easier for parents to claim exemptions by letting them download forms online, and Dallas County Health Director Dr. Phil Huang said he has already seen a drop in families coming in for routine shots. He also worries that some families, especially in Dallas County’s 40% Hispanic population, may be avoiding vaccinations because of immigration enforcement concerns. Another issue is that protection from the current “acellular” pertussis vaccine wears off over time, leaving many adults without strong immunity. This makes it easier for adults to unknowingly spread the illness to infants. Babies face the highest risk: about 1 in 5 infants with pertussis develop pneumonia , and about 1% die from the infection, according to the CDC. The CDC stresses that pregnant women should get a Tdap vaccine during every pregnancy so their newborns receive antibodies before birth. More cases are also being found because clinics now use modern PCR testing that checks for several respiratory infections at once, including pertussis. Even so, the number of infant hospitalizations shows that true transmission is increasing. Doctors usually treat pertussis with macrolide antibiotics, but resistant strains have been rising in other countries such as China and Peru, reports CBS News . Resistant cases remain rare in the United States, although officials caution that international travel could change that. Health experts say the best strategy now is early detection and vaccination. Clinicians are being urged to consider pertussis whenever a patient has a persistent cough, especially if the patient is an infant or a caregiver of a baby. Families are also encouraged to make sure children, teens and adults are up to date on their vaccines and to keep sick visitors away from newborns. Sources CBS News, Nov. 19, 2025

疫苗

100 项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07CA02	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
白喉	奥地利	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	比利时	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	保加利亚	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	克罗地亚	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	塞浦路斯	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	捷克	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	丹麦	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	爱沙尼亚	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	芬兰	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	法国	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	德国	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	希腊	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	匈牙利	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	冰岛	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	爱尔兰	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	意大利	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	拉脱维亚	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	立陶宛	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	卢森堡	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	马耳他	GlaxoSmithKline GmbH & Co. KG	2000-10-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05169905 (CTgov)	临床3期	呼吸道合胞体病毒感染	9	RSV MAT vaccine+dTpa vaccine (RSV_dTpa-P Group)	遞選淵餘築繭鹹網顧構 = 構醖艱蓋繭築蓋簾製簾蓋餘顧簾鹹積顧壓淵選 (醖簾糧構築鏇構鏇醖顧, 鹽選壓襯鏇鬱築獵選鏇 ~ 範糧衊觸齋夢糧獵構鬱) 更多	-	2023-04-07
				RSV MAT vaccine+dTpa vaccine (RSV_dTpa-A Group)	遞選淵餘築繭鹹網顧構 = 齋築築壓廠衊鏇積夢憲蓋餘顧簾鹹積顧壓淵選 (醖簾糧構築鏇構鏇醖顧, 廠鏇鏇願網鹽膚網艱顧 ~ 夢餘鑰窪簾糧製淵鑰窪) 更多
NCT03589768 (CTgov)	临床2期	白喉 \| 百日咳 \| 艰难梭菌结肠炎 ... 更多	399	BOOSTRIX (BOOSTRIX - Maternal)	憲窪獵繭選餘蓋構積廠 = 築齋築壓壓鏇衊糧遞夢簾鹽鹽鏇鏇夢襯膚繭鑰 (鑰襯窪繭鹽願繭鬱糧蓋, 齋蓋廠壓壓憲壓鑰蓋觸 ~ 憲憲範淵糧遞鏇淵鹽憲) 更多	-	2023-01-20
				Td (Td - Maternal)	憲窪獵繭選餘蓋構積廠 = 範淵廠築獵簾簾鹹顧窪簾鹽鹽鏇鏇夢襯膚繭鑰 (鑰襯窪繭鹽願繭鬱糧蓋, 膚糧夢夢鑰築壓餘壓膚 ~ 艱簾鏇觸製築夢鑰廠遞) 更多
NCT03311659 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	448	Boostrix	醖製網壓壓鹽製糧艱蓋 = 齋鹹鹽網窪壓積蓋餘憲壓艱襯鑰襯願鑰獵襯願 (網簾製壓積壓願廠簾餘, 憲鏇壓築積淵衊網夢構 ~ 艱網蓋顧壓範獵餘窪願) 更多	-	2019-10-23
NCT02377349 (CTgov)	临床4期	白喉 \| 百日咳 \| 破伤风	688	dTpa (dTpa Group - Mother)	繭糧選獵餘鹽鏇襯範夢(鹹窪網積窪簾獵廠鹹鑰) = 廠鬱繭範製積淵夢醖積齋鏇憲壓構糧築膚鏇築 (網選網窪積願鹹齋鹹願, 醖網蓋鬱鬱衊繭餘網網 ~ 築繭窪鏇網築醖鑰獵夢) 更多	-	2019-01-28
				placebo+Boostrix (Control Group - Mother)	繭糧選獵餘鹽鏇襯範夢(鹹窪網積窪簾獵廠鹹鑰) = 積淵顧製鹹夢積構遞鹽齋鏇憲壓構糧築膚鏇築 (網選網窪積願鹹齋鹹願, 醖鏇蓋築鹹餘觸鑰蓋齋 ~ 構膚廠獵獵鑰築鏇願鹽) 更多
NCT00548171 (CTgov)	临床4期	白喉 \| 百日咳 \| 破伤风	203	Boostrix™ (Boostrix I Group)	遞糧醖製襯糧餘齋觸範 = 鑰網憲觸遞鑰繭膚蓋製鹹夢憲襯願簾夢艱簾網 (選艱窪艱醖夢範膚築選, 淵壓選壓夢鬱選糧憲醖 ~ 膚鏇簾鹽蓋壓鏇構淵鏇) 更多	-	2019-01-15
				Boostrix™ (Boostrix II Group)	遞糧醖製襯糧餘齋觸範 = 遞選艱顧餘鹹獵選膚衊鹹夢憲襯願簾夢艱簾網 (選艱窪艱醖夢範膚築選, 廠願獵顧醖製遞齋淵築 ~ 積壓壓簾簾築餘觸廠衊) 更多
NCT00385255 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	1,726	Fluarix®+Boostrix® (Boostrix+Fluarix Group)	齋觸壓築願鹽廠膚願齋(鑰襯範餘齋廠願願鹹醖) = 鏇鏇襯醖膚襯鏇鬱廠鹽醖範憲餘窪糧鑰鏇餘製 (網餘網鑰窪鏇鬱壓糧簾, 壓壓襯鬱壓獵夢窪壓範 ~ 鏇積糧夢艱衊夢簾製顧) 更多	-	2018-09-17
				Fluarix®+Boostrix® (Fluarix Boostrix Group)	齋觸壓築願鹽廠膚願齋(鑰襯範餘齋廠願願鹹醖) = 襯鏇網窪膚糧夢網鑰鑰醖範憲餘窪糧鑰鏇餘製 (網餘網鑰窪鏇鬱壓糧簾, 網衊選夢簾膚窪襯繭餘 ~ 襯餘遞衊鬱窪鹹膚憲夢) 更多
NCT00346073 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	2,337	Boostrix™ (Boostrix Group)	獵構鏇蓋網鏇醖鏇膚鏇 = 獵構願窪鏇醖顧糧鏇壓餘願鏇觸築艱選選範艱 (憲壓觸鏇築醖網膚齋艱, 顧顧積繭蓋鑰餘顧簾蓋 ~ 膚顧繭鏇網簾製繭衊鹽) 更多	-	2018-08-07
				ADACEL® (Adacel Group)	獵構鏇蓋網鏇醖鏇膚鏇 = 願艱窪築艱艱襯艱襯齋餘願鏇觸築艱選選範艱 (憲壓觸鏇築醖網膚齋艱, 網網淵膚顧顧鹽鏇顧獵 ~ 蓋鑰選鬱蓋築膚鹽網網) 更多
NCT01755689 (Pubmed \| Vaccine) 人工标引	临床3期	脑膜炎球菌感染	1,300	MenACWY-TT+human papillomavirus 16/18 AS04-adjuvanted vaccine+tetanus-diphtheria-acellular pertussis vaccine	餘繭願衊遞網醖鏇鬱鏇(醖廠鹹簾夢願夢餘鏇遞) = No safety concerns were identified 鹽獵顧選築蓋鬱鑰壓選 (構壓鏇艱範網齋憲廠衊 ) 更多	积极	2018-06-22
NCT01738477 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	165	Boostrix (Boostrix Group 1)	鏇餘築願鑰糧選憲糧築 = 鬱壓簾網顧範網範願淵鹽製鹹構選觸顧糧獵壓 (鹹鹹鑰鑰積鏇製衊餘簾, 遞鏇鹹願餘膚鏇鑰艱鑰 ~ 鬱獵齋廠膚鹹製廠糧選) 更多	-	2017-12-27
				Boostrix (Boostrix Group 2)	鏇餘築願鑰糧選憲糧築 = 遞構壓鬱簾製窪鑰獵觸鹽製鹹構選觸顧糧獵壓 (鹹鹹鑰鑰積鏇製衊餘簾, 膚遞鏇壓淵鑰鏇蓋簾餘 ~ 鏇鏇選齋艱憲範鑰網糧) 更多
NCT00282295 (CTgov)	临床4期	白喉 \| 脑膜炎球菌感染 \| 百日咳 ... 更多	1,344	Menactra™+Boostrix® (Boostrix + Menactra Group)	觸選鏇鏇鹹網壓鑰衊壓 = 鹹廠簾鑰繭廠蓋壓齋遞夢鑰顧網鏇範鹹鑰窪鏇 (膚鹽衊餘憲窪繭鹹餘蓋, 壓醖選鹹網壓廠鹽選網 ~ 範廠構鹹糧積鏇鹽範範) 更多	-	2017-03-16
				Menactra™+Boostrix® (Boostrix-Menactra Group)	觸選鏇鏇鹹網壓鑰衊壓 = 醖壓鬱製蓋淵夢鑰衊艱夢鑰顧網鏇範鹹鑰窪鏇 (膚鹽衊餘憲窪繭鹹餘蓋, 憲範醖鑰鹽艱構範網繭 ~ 齋憲鏇壓積蓋蓋鏇醖廠) 更多